With an AD patient belonging to type 2-dominant endotypes, anti-IL-4Ra antibody dupilumab, blocking both IL-4R type 1 (for IL-4) and type 2 (for IL-4 and IL-13) [42,43] and neutralizing antibodies against IL-13 activity, tralokinumab [44], and lebrikizumab [45] are effective. This evidence concerns the gene IL13 and Alzheimer disease.